{"id":119,"date":"2025-01-03T10:00:00","date_gmt":"2025-01-03T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=119"},"modified":"2025-09-01T10:06:31","modified_gmt":"2025-09-01T10:06:31","slug":"china-bd-2025-innovent-and-roche-enters-a-1-billion-license-on-dll3-adc-ibi3009","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/119.html","title":{"rendered":"[China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009"},"content":{"rendered":"\n<p>Announced Date: 2025-01-02 (January 2, 2025)<\/p>\n\n\n\n<p>Asset Name: IBI3009<\/p>\n\n\n\n<p>Licensor: Innovent (Innovent Biologics, Inc.\uff0cChina)<\/p>\n\n\n\n<p>Licensee (Buyer): Roche<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: ADC (antibody drug conjugate)\u00a0<\/p>\n\n\n\n<p>Asset Target: DLL3<\/p>\n\n\n\n<p>Potential Indication: small cell lung cancer<\/p>\n\n\n\n<p>Current Stage: Phase 1 <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: \u00a0<\/p>\n\n\n\n<p>Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009. <\/p>\n\n\n\n<p>The two parties will jointly focus on the early-stage development of this ADC candidate, after which Roche will take over full development. <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment  of  $80 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$1 billion.<\/p>\n\n\n\n<p>Tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate<\/p>\n\n\n\n<p><a href=\"https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=499\">https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=499<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-01-02 (January 2, 2025) Asset Name: IBI3009 Licensor: Innovent (Innovent Biologics, Inc.\uff0cChina) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/119.html\"><span class=\"screen-reader-text\">[China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-119","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=119"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/119\/revisions"}],"predecessor-version":[{"id":121,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/119\/revisions\/121"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}